Purpose of Review <p>This review focuses on the cardiovascular toxicities linked to both traditional chemotherapy and newer targeted cancer therapies. The objective is to examine the mechanisms behind these toxicities, their clinical implications, and current strategies for detection, prevention, and management. The paper aims to inform ongoing clinical decision-making and highlight areas where evolving evidence can enhance the safety and effectiveness of cancer care.</p> Recent Findings <p>Cardiotoxicity is no longer confined to legacy agents like anthracyclines. New classes of therapies, including HER2-targeted treatments, tyrosine kinase inhibitors, VEGF inhibitors, and antibody-drug conjugates, have been linked to unique cardiac side effects ranging from hypertension and arrhythmias to heart failure. Off-target interactions, cumulative drug exposure, and individual patient susceptibility often influence these effects. Additionally, radiation therapy, particularly in the thoracic region, continues to contribute to late-onset cardiovascular disease. Advances in cardiac imaging, strain-based assessment, biomarker profiling, and clinical risk models may help identify high-risk individuals earlier and more accurately.</p> Summary <p>Cardiotoxicity remains a significant concern in delivering effective care to patients with cancer, impacting both short-term treatment outcomes and long-term survivorship. While traditional agents have well-characterized risks, modern therapies require refined monitoring strategies. Future care will depend on personalized approaches, early identification tools, and interdisciplinary collaboration to optimize cardiovascular health without compromising cancer outcomes.</p>